0001654954-18-013649.txt : 20190226 0001654954-18-013649.hdr.sgml : 20190226 20181206155429 ACCESSION NUMBER: 0001654954-18-013649 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20181206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC. CENTRAL INDEX KEY: 0000034956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 262593535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-806-4414 MAIL ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC. DATE OF NAME CHANGE: 20080703 FORMER COMPANY: FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SINEQUANON CORP DATE OF NAME CHANGE: 19901219 CORRESP 1 filename1.htm Blueprint
 
 
December 6, 2018
 
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-0306
 
Attn:
Ruairi Regan
 
Division of Corporation Finance
 
Re:
Tenax Therapeutics, Inc.
 
Registration Statement on Form S-1
 
No. 333-228212
 
Withdrawal of Request for Acceleration
 
Dear Mr. Regan:
 
Reference is made to our letter, filed as correspondence via EDGAR on December 4, 2018, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Thursday, December 6, 2018, at 4:30 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
 
If you have any questions, please contact me at (919) 855-2123. Thank you in advance for your assistance.
 
 
Sincerely,
 
 
 
/s/ Michael B. Jebsen
 
Michael B. Jebsen
 
President and Chief Financial Officer
 
cc:
Margaret N. Rosenfeld
 
Partner, Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.